Amarin (NASDAQ:AMRN – Get Free Report) and BeOne Medicines (NASDAQ:ONC – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Amarin and BeOne Medicines, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amarin | 2 | 1 | 0 | 0 | 1.33 |
| BeOne Medicines | 0 | 1 | 16 | 1 | 3.00 |
Amarin currently has a consensus target price of $13.00, indicating a potential upside of 14.24%. BeOne Medicines has a consensus target price of $440.56, indicating a potential upside of 5.77%. Given Amarin’s higher probable upside, research analysts plainly believe Amarin is more favorable than BeOne Medicines.
Risk & Volatility
Amarin has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
Institutional & Insider Ownership
22.3% of Amarin shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Amarin and BeOne Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amarin | -10.87% | -0.52% | -0.36% |
| BeOne Medicines | 13.86% | 19.04% | 10.70% |
Valuation and Earnings
This table compares Amarin and BeOne Medicines”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amarin | $213.65 million | 1.12 | -$38.80 million | ($0.96) | -11.85 |
| BeOne Medicines | $5.34 billion | 8.56 | $286.93 million | $7.87 | 52.93 |
BeOne Medicines has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Summary
BeOne Medicines beats Amarin on 13 of the 15 factors compared between the two stocks.
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on cardiovascular health. Its principal product is VASCEPA, a prescription medicine containing icosapent ethyl, an omega-3 fatty acid derivative. In the United States, VASCEPA is approved for use with a statin and other measures to reduce the risk of certain cardiovascular events in eligible adults with elevated triglycerides. It is also approved as an adjunct to diet to lower triglyceride levels in adults with severe hypertriglyceridemia.
About BeOne Medicines
BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
